As a further validation, ANXA2 inhibition/silencing were both able to halve the number of ANXA2hi GBM cells able to pass through a basal membrane extract (BME)-coated transwell (CultreCoat®Cell Invasion assay) within 48 h (Figure 4E, 4F and Supplementary Figure S8B, S8C). This evidence concerns the gene ANXA2 and glioblastoma.